FDA
-
MoreFDA Fronts Pivotal Life Sciences Trend in 2020
This publication provides an in-depth look at the FDA’s transformation and addresses how the agency’s initiative will impact manufacturers of regulated products.
-
MoreCommon Reasons for FDA 483 Inspectional Observations in Biologics Manufacturing Environments
Learn about the most common 483 observations and audit findings, and avoid warning letters by staying compliant and addressing issues in the stipulated time period.
-
MoreAnnex 11 and 21 CFR Part 11: Comparisons for International Compliance
The two essential resources regarding the validation of computer systems are: the FDA’s 21 CFR Part 11 and the EMEA Guidelines to Good Manufacturing Practice (GMPs) - Annex 11, Computerized Systems.
-
More21 CFR Part 11 Compliance Checklist
If your company is planning to convert to an automated system for managing documents and processes, make sure the new system meets the needs outlined in this 21 CFR Part 11 Compliance Checklist.
-
0:00MoreThe FDA Just Called - Now What
-
1:20MoreCompleting an FDA Inspection With MasterControl
MasterControl customer Contract Pharmacal Corporation used to be a paper-based organization. They’ve greatly benefited from switching to MasterControl’s electronic quality management system (QMS).
-
0:00MoreThe FDA Just Called - Now What
-
MoreFDA/ISO Compliance Toolkit
Medical device managers are complying with FDA requirements and better aligning with evolving industry trends by recognizing the value of moving to a digital quality management system.
-
MoreTen Most Common Reasons for FDA 483 Inspectional Observations in Pharmaceutical Environments
The U.S. Food and Drug Administration has released data on the most common observations it makes during inspections of pharmaceutical facilities. This white paper explores the top 10 deficiences.
-
MoreFDA Inspections of Clinical Investigators: Are You Ready?
In the United States, the Food and Drug Administration (FDA) has a number of guidances that are meant to strengthen its oversight of clinical investigators and clinical trials.
-
MoreValidating Software Systems to Comply with CGMP and 21 CFR Part 11 Regulations
-
More11 Free Resources to Boost Your Medical Device FDA Readiness
This FDA Readiness Toolkit is designed to help medical device manufacturers simplify compliance with FDA standards and streamline quality-related processes.
-
MoreHow to Successfully Complete an FDA Inspection
This white paper provides an overview of the inspection process, describing the preparation for an inspection, what will happen during an inspection, and what to expect after an inspection occurs.
-
MoreThe Value of Studying and Utilizing FDA's QSIT Manual
The FDA’s approach to the inspection process of medical device manufacturers, Quality System Inspection Technique (QSIT), embraces a top-down inspection of a firm’s QMS.
-
MoreMasterControl eMDR™
The FDA requires medical device manufacturers to report any adverse events to the agency.
-
51:38MoreWorking on a Post-Inspection FDA Response - MasterControl
After an FDA investigator has inspected your facility and issued a Form 483, it is critical to meet the post-inspection response requirements. Failure to do so can have devastating consequences.
-
49:13MoreAfter an FDA Inspection
MasterControl quality and compliance expert Walt Murray presents what needs to happen in the wake of a U.S. Food and Drug Administration (FDA) inspection.
-
More11 Free Resources to Boost Your FDA Readiness
A collection of related videos, whitepapers, articles, and product data sheets to simplify compliance with FDA standards by streamlining quality-related processes.
-
More12 Free Resources to Boost Your Pharmaceutical FDA Readiness
This FDA Readiness Toolkit is designed to help pharmaceutical companies simplify compliance with FDA standards and streamline quality processes.
-
55:55MoreThe FDA Just Called! Now What?
-
Loading More...
